Anti-TACI antibody (Biotin) (ab83515)
- Datasheet
- Specific References (1)
- Protocols
Overview
-
Product nameAnti-TACI antibody (Biotin)
See all TACI primary antibodies -
DescriptionGoat polyclonal to TACI (Biotin)
-
ConjugationBiotin
-
Tested applicationsSuitable for: ELISA, Sandwich ELISA, WB, IPmore details
-
Species reactivityReacts with: Human
-
Immunogen
Highly pure (>98%) recombinant human TACI
-
General notesab83515 is sterile filtered.
Properties
-
FormLyophilised:Centrifuge vial prior to opening. Reconstitute in sterile PBS containing 0.1% BSA to a concentration of 0.1-1.0 mg/ml.
-
Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Store at -20°C or -80°C. Avoid freeze / thaw cycle.
-
Storage bufferPreservative: None
Constituents: PBS, pH 7.2 -
Concentration information loading... -
PurityImmunogen affinity purified
-
ClonalityPolyclonal
-
IsotypeIgG
-
Research areas
Associated products
-
Compatible Secondaries
-
sELISA pair antibody
Applications
Our Abpromise guarantee covers the use of ab83515 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
| Application | Abreviews | Notes |
|---|---|---|
| ELISA | ||
| Sandwich ELISA | ||
| WB | ||
| IP |
Application notes
ELISA: Use at a concentration of 0.25 - 1 µg/ml. Allows the detection of at least 0.2 - 0.4 ng/well of recombinant human TACI.
sELISA: Use at a concentration of 0.25 - 1 µg/ml. Allows the detection of at least 0.2 - 0.4 ng/well of recombinant human TACI.
WB: Use at a concentration of 0.1 - 0.2 µg/ml. The detection limit for recombinant human TACI is 1.5 - 3.0 ng/lane, under either reducing or non-reducing conditions. Predicted molecular weight: 32 kDa.
Not yet tested in other applications.
Optimal dilutions/concentrations should be determined by the end user.
sELISA: Use at a concentration of 0.25 - 1 µg/ml. Allows the detection of at least 0.2 - 0.4 ng/well of recombinant human TACI.
WB: Use at a concentration of 0.1 - 0.2 µg/ml. The detection limit for recombinant human TACI is 1.5 - 3.0 ng/lane, under either reducing or non-reducing conditions. Predicted molecular weight: 32 kDa.
Not yet tested in other applications.
Optimal dilutions/concentrations should be determined by the end user.
Target
-
FunctionReceptor for TNFSF13/APRIL and TNFSF13B/TALL1/BAFF/BLYS that binds both ligands with similar high affinity. Mediates calcineurin-dependent activation of NF-AT, as well as activation of NF-kappa-B and AP-1. Involved in the stimulation of B- and T-cell function and the regulation of humoral immunity.
-
Tissue specificityHighly expressed in spleen, thymus, small intestine and peripheral blood leukocytes. Expressed in resting B-cells and activated T-cells, but not in resting T-cells.
-
Involvement in diseaseDefects in TNFRSF13B are the cause of immunodeficiency common variable type 2 (CVID2) [MIM:240500]. CVID2 is a primary immunodeficiency characterized by antibody deficiency, hypogammaglobulinemia, recurrent bacterial infections and an inability to mount an antibody response to antigen. The defect results from a failure of B-cell differentiation and impaired secretion of immunoglobulins; the numbers of circulating B cells is usually in the normal range, but can be low.
Defects in TNFRSF13B are a cause of immunoglobulin A deficiency 2 (IGAD2) [MIM:609529]. Selective deficiency of immunoglobulin A (IGAD) is the most common form of primary immunodeficiency, with an incidence of approximately 1 in 600 individuals in the western world. Individuals with symptomatic IGAD often have deficiency of IgG subclasses or decreased antibody response to carbohydrate antigens such as pneumococcal polysaccharide vaccine. Individuals with IGAD also suffer from recurrent sinopulmonary and gastrointestinal infections and have an increased incidence of autoimmune disorders and of lymphoid and non-lymphoid malignancies. In vitro studies have suggested that some individuals with IGAD have impaired isotype class switching to IgA and others may have a post-switch defect. IGAD and CVID have been known to coexist in families. Some individuals initially present with IGAD1 and then develop CVID. These observations suggest that some cases of IGAD and CVID may have a common etiology. -
Sequence similaritiesContains 2 TNFR-Cys repeats.
-
Cellular localizationMembrane.
- Information by UniProt
-
Database links
- Entrez Gene: 23495 Human
- Omim: 604907 Human
- SwissProt: O14836 Human
- Unigene: 158341 Human
-
Alternative names
- CD 267 antibody
- CD267 antibody
- CD267 antigen antibody
see all
References for Anti-TACI antibody (Biotin) (ab83515)
This product has been referenced in:
- Romberg N et al. CVID-associated TACI mutations affect autoreactive B cell selection and activation. J Clin Invest 123:4283-93 (2013). IP ; Human . Read more (PubMed: 24051380) »
Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"